The quest for competitive sustainability: From technology sourcing to knowledge management

Journal of Technology Management and Innovation

Volumn 4, Issue 2, 2009, Pages 54-68

  Amir Aslani, Arsia ^a  

^a Araxes Associates   (France)

Author keywords

Biotechnology; Competitive dynamics; Innovation; Knowledge management; Organizational learning; Technology sourcing

Indexed keywords

EID: 70349621623     PISSN: None     EISSN: 07182724     Source Type: Journal    
DOI: 10.4067/S0718-27242009000200005     Document Type: Article

References (56)

1. AHUJA, G., Katila, R., (2001) Technological acquisitions and the innovation performance of acquiring firms: a longitudinal study. Strategic Management Journal, 22, 197-220.
2. AHUJA, G., Katila R., (2004) Where do resources come from? The role of idiosyncratic situations. Strategic Management Journal, 25, 887-907.
3. AUDRETSCH, D., Feldman, M., (2003) Small-Firm strategic research partnerships: The case of biotechnology. Technology Analysis & Strategic Management, 15, 273-288.
4. BLEEKE, J., Ernst, D., (1995) Is your strategic alliance really a sale? Harvard Business Review, January-February.
5. BIOCENTURY Extra., (2000) Biocentury 20 November 2000.
6. CASSIMAN, B., Veugelers, R., (2006) In search of complementarity in innovation strategy: internal R&D and external knowledge acquisition. Management Science, 52, 68-82.
7. CHESBROUGH, H.W., (2003) Open innovation: the new imperative for creating and profiting from technology. Harvard Business School Press, Cambridge, MA.
8. COCKBURN, I.M., Henderson, R.M., (1998) Absorptive capacity, coauthoring behavior, and the organization of research in drug discovery. Journal of Industrial Economics, 46, 157-182.
9. COHEN, W.M., Levinthal, D.A., (1990) Absorptive capacity: a new perspective on learning and innovation. Administrative Science Quarterly, 32, 128-152.
10. COOMBS, R., Hull, R., (1998) Knowledge management practices' and path-dependency in innovation. Research Policy, 27, 237-253.
11. CZEREPAK, E.A., Ryser, S., (2008) Drug approvals and failures: implications for alliances. Nature Reviews Drug Discovery, 7, 197-198.
12. DANZON, P.M., Nicholson, S., Sousa Pereira, N., (2005) Productivity in pharmaceutical-biotechnology R&D: the role of experience and alliances. Journal of Health Economics 24, 317-339.
13. DAS, T.K., Teng, B-S., (1996) Risk types and inter-firm alliance structures. Journal of Management Studies, 33, 827-843.
14. DAS, T.K., Teng, B-S., (2000) A resource based theory of strategic alliances. Journal of Management, 26, 31-61.
15. DEEDS, D.L., DeCarlois, D., Coombs, J., (2000) Dynamic capabilities and new product development in high technology ventures: An empirical analysis of new biotechnology firms. Journal of Business Venturing, 15, 211-229.
16. DIERICKX, I., Cool, K., (1989) Asset stock accumulation and sustainability of competitive advantage. Management Science, 35, 1504-1511.
17. DIMASI, J., (2001) Risks in new drug development: approval success rates for investigational drugs. Clinical Pharmacology & Therapeutics, 69, 297-307.
18. DUYSTERS, G., Hagedorn, J., (2000) Core competencies and company performance in the worldwide computer industry. Journal of High Technology Management Research, 11, 75-91.
19. EISENHARDT, K.M., Martin, J.A., (2000) Dynamic capabilities: what are they? Strategic Management Journal, 21, 1105-1121.
20. GALAMBOS, L., Surchio, J.L., (1998) Pharmaceutical firms and the transition to biotechnology: a study in strategic innovation. The Business History Review, 72, 250-278.
21. GAMBARDELLA, A., (1995) Science and Innovation: The US Pharmaceutical Industry during the 1980s. Cambridge University Press.
22. GRANT, R.M., Baden-Fuller, C., (2004) A knowledge accessing theory of strategic alliances. Journal of Management Studies, 41, 61-84.
23. GULATI, R., Nohria, N., Zaheer, A., (2000) Strategic networks. Strategic Management Journal, 21, 203-215.
24. HENDERSON, R., Cockburn, I., (1996) Scale, scope, and spillovers: The determinants of research productivity in drug discovery. RAND Journal of Economics, 27, 32-59.
25. HENDERSON, R., Cockburn, I., (1996) Measuring competence? Exploring firm effects in drug discovery. Strategic Management Journal, 15, 63-84.
26. HUGHES, B., (2008) 2007 FDA drug approvals: a year of flux. Nature Reviews Drug Discovery, 7. 107-109.
27. INKPEN, A.C., (2000) Learning through joint ventures: A framework of knowledge acquisition. Journal of Management Studies, 37, 1019-1044.
28. JONES, G., Lanctot, A., Teegen, H.J., (2001) Determinants and performance impacts of extrernaly technology acquisition. Journal of Business Venturing, 16, 255-283.
29. KIM, D-J., Kogut, B., (1996) Technological platforms and diversification. Organization Science, 7, 283-301.
30. KOGUT, B., (1989) The stability of joint ventures: Reciprocity and competitive rivalry. Journal of Industrial Economics, 38, 183-198.
31. LAWRENCE, S., (2007) State of he biotech sector - 2006. Nature Biotechnology, 25. 706.
32. MCKELVEY, M., Alm, H., Riccaboni, M., (2003) Does co-location matter for formal knowledge collaboration in the Swedish biotechnology. Research Policy, 32, 483-501.
33. MANSFIELD, E., (1995) Academic research underlying industrial innovation. Review of Economics and Statistics, 77, 55-65.
34. MATHEWS, A.J. (2003) Strategizing by firms in the presence of markets for resources. Industrial & Corporate Change 12, 1157-1193.
35. MCNAMARA, P., Baden-Fuller, C., (1999) Lessons from the Celltech case: Balancing knowledge exploration and exploitation in organizational renewal. British Management Journal, 10, 291-307.
36. NEWBERT, S.L., (2007) Empirical research on the resource-based view of the firm: an assessment and suggestions for future research. Strategic Management Journal, 28, 121-146.
37. Nicholls-Nixon, L.C., Woo, Y.C., (2003) Technology sourcing and output of established firms in a regime of encompassing technological change. Strategic Management Journal, 24, 651-666.
38. NIOSI, J., (2003) Alliances are not enough explaining rapid growth in biotechnology firms. Research Policy, 32, 737-750.
39. PETERAF, A.M., (1993) The cornerstones of competitive advantage: A Resource-Based View. Strategic Management Journal, 14, 179-191.
40. PISANO, P.G., (1990) The R&D Boundaries of the firm: An empirical analysis. Administrative Science Quarterly, 35, 153-176.
41. POWELL, W., Kogut, K., Smith-Doerr, L., (1996) Interorganizational collaboration and the locus of innovation: networks of learning in biotechnology. Administrative Science Quarterly, 41, 116-145.
42. PRABHU, J.C., Chandy, R.K., Ellis, M.E. (2005) The impact of acquisitions on innovation: poison pill, placebo, or tonic? Journal of Marketing, 69, 114-120.
43. ROSENKOPF, L., Nerkar, A., (2001) Beyond local search: Boundary-Spanning, exploration, and impact in the optical disk industry. Strategic Management Journal, 22, 287-306.
44. ROSENKOPF, L., Almeida, P., (2003) Overcoming local search through alliances and mobility. Management Science, 49, 751-766.
45. ROTHAERMEL, F., Deeds, D., (2004) Exploration and exploitation alliances in biotechnology: a system of new product development. Strategic Management Journal, 25, 201-221.
46. SCHWEIZER, L., (2005) Organizational Integration of acquired biotechnology companies into pharmaceutical companies: The need for a hybrid approach. Academy of Management Journal, 48, 1051-1074.
47. SHAN, W., Walker, G., Kogut, B., (1994) Interfirm cooperation and startup Innovation in the biotechnology industry. Strategic Management Journal, 15, 387-394.
48. SMITH, R., Sharif, N., (2007) Understanding and acquiring technology assets for global competition. Technovation, 27, 643-649.
49. TSAI, K.-H., Wang, J.-C., (2008) External technology acquisition and firm performance: A longitudinal study. Journal of Business Venturing, 23, 91-112.
50. VAN ROOIJ, A., (2005) Why do firms acquire technology? The example of DSM's ammonia plants, 1925-1970. Research Policy, 34, 836-851.
51. VERMEULEN, F., Barkema, H., (2001) Learning through acquisitions. Academy of Management Journal, 44, 457-476.
52. WALSH, G., (2003a) Pharmaceutical biotechnology products approved within the European Union. European Journal of Pharmaceutics and Biopharmaceutics, 55, 3-10.
53. WALSH, G., (2006) Biopharmaceutical benchmarks 2006. Nature Biotechnology, 24, 769-776.
54. WALTER, G.A., Barney, J.B., (1990) Management objectives in mergers and acquisitions. Strategic Management Journal, 11, 79-86.
55. ZAHRA, S.A., (1996) Technology strategy and new venture performance: a study of corporate sponsored and independent biotechnology ventures. Journal of Business Venturing, 11, 289-321.
56. ZOLLO, W., Winter, S.G., (2002) Deliberate learning and the evolution of dynamic capabilities. Organization Science, 13, 339-351.